Top 10 High Dividend Stocks For 2015

Looking for a new “get rich quick” scheme? Head down to South Texas and start drilling wells in the Eagle Ford Shale then, as nearly every company with acreage down there is experiencing outstanding production right now. Production in the play popped 74% year over year in February, bringing production to about 471,000 barrels per day. Today I’ll highlight three players reaping the Eagle Ford’s benefits, as well as the one poor exploration and production company that goofed and somehow lost money in South Texas.

Show everyone the money
We’ll start with Anadarko Petroleum (NYSE: APC  ) . The company recently announced that sales of crude oil and natural gas liquids in the Eagle Ford jumped 60% year over year, to 28,000 barrels per day. The company plans to bring a natural gas processing plant on line this quarter, which should have a capacity of 200 million cubic feet per day.

Moving on to Chesapeake Energy (NYSE: CHK  ) , the debt-ridden natural gas producer is reporting that the Eagle Ford is the driving force behind a big increase in the company’s oil production. Management expects to produce 1 million barrels of oil more than originally anticipated, on account of drilling longer laterals, better than expected well results, and sufficient midstream infrastructure– which is something that is currently holding back Chesapeake’s production in the Marcellus Shale.

Top 10 High Dividend Stocks For 2015: Cadence Pharmaceuticals Inc.(CADX)

Cadence Pharmaceuticals, Inc., a biopharmaceutical company, focuses on acquiring, in-licensing, developing, and commercializing proprietary product candidates principally for use in the hospital setting in the United States and Canada. It holds rights to OFIRMEV injection, a proprietary intravenous formulation of acetaminophen for the management of pain and reduction of fever in adults and children. The company in-licenses rights to OFIRMEV from Bristol-Myers Squibb Company, which sells intravenous acetaminophen in Europe and other markets for the treatment of acute pain and fever under the Perfalgan brand name. Cadence Pharmaceuticals, Inc. was founded in 2004 and is headquartered in San Diego, California.

Advisors’ Opinion:

  • [By Jake L’Ecuyer]

    Equities Trading UP
    Cadence Pharmaceuticals (NASDAQ: CADX) shot up 26.42 percent to $14.02 after Mallinckrodt plc (NYSE: MNK) announced its plans to acquire Cadence Pharma for $14.00 per share in cash.

  • [By Paul Ausick]

    Stocks on the Move: Zulily Inc. (NASDAQ: ZU) is up 71.4% at $37.70 after its IPO today. Cadence Pharmaceuticals Inc. (NASDAQ: CADX) is up 33.8% at $7.87 on a patent ruling. Electronic Arts Inc. (NASDAQ: EA) is down 7.4% at $24.04.

Top 10 High Dividend Stocks For 2015: Ishares S&P Midcap 400 Index Fund (IJH)

iShares S&P MidCap 400 Index Fund (the Fund) seeks investment results that correspond generally to the price and yield performance of the Standard & Poor’s MidCap 400 Index (the Index). The Index measures the performance of the mid-capitalization sector of the United States equity market. The Index serves as the underlying index for the S&P 400/Citigroup Growth and Value Index series. The components stocks are weighted according to the total float-adjusted market value of their outstanding shares. The component stocks have a market capitalization between $1 billion and $4 billion (which may fluctuate depending on the overall level of the equity markets), and are selected for liquidity and industry group representation.

The Index is adjusted to reflect changes in capitalization resulting from mergers, acquisitions, stock rights, substitutions and other capital events. The Fund invests in a representative sample of securities included in the Index that collec tively has an investment profile similar to the Index. The Fund’s investment advisor is Barclays Global Fund Advisors.

Advisors’ Opinion:

  • [By John Udovich]

    Moreover, my guess is that the switch will be a wash for investors as funds and ETFs that track the S&P 500 will dump their positions in Advanced Micro Devices and SAIC Inc while those that track the S&P Mid Cap 400 will be obligated to take up positions in both. A quick look at the performance of the iShares S&P 500 Index ETF (NYSEARCA: IVV) verses the iShares Core S&P Mid Cap ETF (NYSEARCA: IJH) reveals the following:

Top 10 High Dividend Stocks For 2015: Protalix Biotherapeutics Inc (PLX)

Protalix BioTherapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its ProCellEx protein expression system, ProCellEx. Using its ProCellEx system, the Company is developing a pipeline of biosimilar or generic versions of recombinant therapeutic proteins based on its plant cell-based expression technology, which focuses pharmaceutical markets and that rely upon known biological mechanisms of action. ProCellEx protein expression system consists of a set of technologies and capabilities for the development of recombinant proteins, including advanced genetic engineering technology and plant cell-based protein expression methods. Its ProCellEx protein expression system is built on flexible custom-designed bioreactors made of polyethylene and optimized for the development of complex proteins in plant cell cultures. In June 2010, it had completed the preliminary phase I clinical trial of PRX- 105.

Taliglucerase Alfa

Taliglucerase alfa is a plant cell expressed recombinant glucocerebrosidase enzyme (GCD) for the treatment of Gaucher disease. The Company has commenced pre-clinical studies of an oral form of taliglucerase alfa. Its oral taliglucerase alfa is a plant cell expressed form of GCD that is naturally encapsulated within carrot cells genetically engineered to express the GCD enzyme. Pre-clinical studies of oral taliglucerase alfa demonstrate the stability of the enzyme in the cell and the capacity of the cell’s cellulose wall to protect the enzyme against degradation in the digestive tract in an in-vitro model of the stomach and intestines. Additionally, rats fed with lyophilized carrot cells expressing GCD have accumulated the active enzyme in the target organs; the spleen and liver. As of December 31, 2010, the Company had completed Phase III Clinical Trial.

PRX-102

The Company is developing PRX-102, i ts plant cell expressed modified version of the recombinant ! alpha-GAL-A protein, a therapeutic enzyme for the treatment of Fabry disease. Fabry disease is a rare, hereditary, genetic lysosomal storage disorder in humans caused by an X-lined deficiency of the alpha-GAL-A enzyme. The Company is in the animal evaluation testing phase of the development of PRX-102, which tests are based on a mouse model for Fabry disease.

Acetylcholinesterase

Protalix Ltd. is a wholly owned subsidiary of the Company is licensed the rights to certain technology under a research and license agreement with Yissum Research and Development Company (Yissum) and the Boyce Thompson Institute, Inc. Pursuant to the agreement, the Company is developing PRX-105, a plant cell-based acetylcholinesterase (AChE) and its molecular variants for the use in several therapeutic and prophylactic indications, as well as in a biodefense program and an organophosphate-based pesticide treatment program.

As of December 31, 2010, its in-vitr o experiments of PRX-105 have shown that the acetylcholinesterase enzyme in its ProCellEx protein expression system demonstrates biological activity on biochemical and cellular levels. In addition, early animal studies demonstrated that the acetylcholinesterase expressed in its ProCellEx protein expression system was able to treat animals exposed to the nerve gas agent analogues, both when injected with its acetylcholinesterase product candidate immediately before exposure or when injected after exposure. In March 2010, it initiated a preliminary phase I clinical trial of PRX-105, which the Company completed in June 2010.

pr-antiTNF

pr-antiTNF is a candidate for the treatment of certain autoimmune diseases such as rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing, spondylitis, psoriatic arthritis and plaque psoriasis. The Company has designed the antiTNF as pr-antiTNF. pr-antiTNF is a plant cell-expressed recombinant fusion protein ma de from the soluble form of the human TNF receptor (TNFR), f! used to t! he Fc component of a human antibody domain. pr-antiTNF has an identical amino acid sequence to Enbrel and its in-vitro and preclinical animal studies have demonstrated that pr-antiTNF exhibits similar activity to Enbrel. Specifically, pr-antiTNF binds TNF thereby inhibiting it from binding to cellular surface TNF receptors and protects L929 cells from TNF-induced apoptosis in a dose-dependent manner.

The Company competes with Genzyme, Actelion, Crucell N.V., Biolex, Inc., Chlorogen, Inc., Greenovation Biotech GmbH, Symbiosys, Novartis AG/Sandoz Pharmaceuticals, BioGeneriX AG, Stada Arzneimittel AG, BioPartners GmbH and Teva.

Advisors’ Opinion:

  • [By Maxx Chatsko]

    Industrial biotech isn’t the only industry headed to Brazil. Protalix (NYSEMKT: PLX  ) entered into a technology transfer agreement with Brazil’s Ministry of Health last week that will pay the company $280 million. The deal is big news for Protalix’s first product, Elelyso/Uplyso, which was developed with partner Pfizer (NYSE: PFE  ) . The treatment is approved as an enzyme replacement therapy, or ERT, for adults with type 1 Gaucher disease, and it marks a huge step forward for the future of biomanufacturing. In the following video, Fool contributor Maxx Chatsko explains what this means for the product’s commercialization and the adoption of Protalix’s novel plant cell-based expression system for therapeutic proteins.

  • [By Keith Speights]

    Other investors might wish that Pfizer would use some of its cash to acquire a few smaller companies. Protalix BioTherapeutics (NYSEMKT: PLX  ) has been mentioned as one possible candidate. The two companies already partner together on Gaucher disease drug Elelyso. In February, Protalix spurred rumors that Pfizer could be interested in buying the company after it announced that it had engaged Citigroup to pursue a “broad array of strategic alternatives.”

Top 10 High Dividend Stocks For 2015: Computer Programs and Systems Inc.(CPSI)

Computer Programs and Systems, Inc., a healthcare information technology company, designs, develops, markets, installs, and supports computerized information technology systems to small and midsize hospitals in the United States. Its enterprise-wide system automates the management of clinical and financial data across the primary functional areas of a hospital. The company offers services that enable customers to outsource certain data-related business processes in the areas of clinical care, revenue cycle management, cost control, and regulatory compliance. Its software products include Patient Management, which enables a hospital to identify a patient at any point in the healthcare delivery system, and to collect and maintain patient information through the process of patient care; Financial Accounting that provides various business office applications to track and coordinate information needed for managerial decision-making; and Clinical, which automates record keeping and reporting for a range of clinical functions, such as laboratory, radiology, physical therapy, respiratory care, and pharmacy. The company?s software products also comprise Patient Care that allows hospitals to create computerized patient files; and Enterprise Applications, which provide software applications that support its products for use in various areas of the hospital. In addition, it offers support and maintenance services; business management services, including electronic billing, statement processing, accounts receivable management, payroll processing, contract management, and insurance services; and system implementation and training services, such as conversion and training. Further, the company sells computer hardware, peripherals, forms, and office supplies. It serves acute care community hospitals; and small specialty hospitals that focus on medical areas, such as surgery, rehabilitation, and psychiatry. The company was founded in 1979 and is headquartere d in Mobile, Alabama.

Advisors’ Opinion:

  • [By John Udovich]

    In the wake of the Obamacare fiasco, small cap healthcare information systems stock Computer Programs & Systems, Inc (NASDAQ: CPSI) has put in a good performance, meaning its worth taking a closer look at the stock along with the performance of large cap players like Cerner Corporation (NASDAQ: CERN) and McKesson Corporation (NYSE: MCK) and small cap Quality Systems, Inc (NASDAQ: QSII).

  • [By Sally Jones]

    Both CSP Inc. (CPSI) and ITT Educational Services Inc. (ESI) have struggled in the last year. Their revenues are way down as of the second quarter, year over year. Richard Blum’s Blum Capital Partners LP continues to trim sinking education companies where the company is 10% owner, and John Rogers of Ariel Capital Management cuts a long-held defense company that delivered high gains over five years.

Top 10 High Dividend Stocks For 2015: LaSalle Hotel Properties (LHO)

LaSalle Hotel Properties, a real estate investment trust (REIT), engages in the purchase, ownership, redevelopment, and leasing of primarily upscale and luxury full-service hotels in convention, resort, and urban business markets in the United States. It owns 34 hotels, totaling approximately 9,200 guest rooms in 15 markets in 11 states and the District of Columbia. The company qualifies as a REIT under the Internal Revenue Code of 1986. As a REIT, it would not be subject to federal corporate income tax to the extent that it distributes at least 90% of its taxable income to its shareholders. The company was founded in 1998 and is based in Bethesda, Maryland.

Advisors’ Opinion:

  • [By Rich Duprey]

    Upscale hotel operator LaSalle Hotel Properties (NYSE: LHO  ) announced yesterday its third-quarter dividend of $0.28 per share, a 40% increase in the payout made to investors from the $0.20 per share paid last quarter.

  • [By Marshall Hargrave]

    The other key benefit for Strategic is that it enjoys industry-leading earnings before interest, taxes, depreciation and amortization (EBITDA) per available room. For 2012, Strategic generated $81 per room of EBITDA. Compare this to top comps LaSalle Hotel (NYSE: LHO) at $74 per room and Pebblebrook Hotel Trust (NYSE: PEB) at $71. The reason for this is that Strategic is much less reliant than its peers on rooms, with much greater exposure to food and beverages. Strategic earns 53% of its revenue from rooms, while its peers get around 66% of revenues from rooms.

Top 10 High Dividend Stocks For 2015: International Northair Mines Ltd (INM)

International Northair Mines Ltd is a mineral exploration company engaged in the acquisition, exploration and development of mineral properties throughout North America with a focus in Mexico. In Mexico, exploration is conducted by its wholly owned subsidiary, Grupo Northair de Mexico, S.A. de C.V. (Grupo Northair). Its projects include La Cigarra Project, Sierra Rosario Project, and El Reventon Project. The La Cigarra Project is located near the municipality of Parral, in the State of Chihuahua in north central Mexico. La Cigarra consists of mineral concessions totaling approximately 32,000 hectares. The El Reventon Project is located in the municipality of Otaez, Durango and is approximately 170 kilometers northwest of the capital city of Durango. The El Reventon Project consists of approximately 3,400 hectares. Sierra Rosario silver/gold project is staked by the Company and joint ventured to American Consolidated Minerals Resources Corp., which has a 50% interest in the pr operty. Advisors’ Opinion:

  • [By Alexis Xydias]

    The ISEQ Index (ISEQ) in Ireland and the ASE Index in Greece, the first two nations to receive European Union-led bailouts, have soared more than 28 percent this year to lead gains among 18 national benchmarks in western Europe. Dublin-based Independent News & Media Plc (INM) and Athens-based Aegean Airlines SA (AEGN) rose the most, with jumps of more than 180 percent. Germany’s DAX Index (DAX) has advanced 18 percent in 2013, reaching a record.

Top 10 High Dividend Stocks For 2015: Savient Pharmaceuticals Inc(SVNT)

Savient Pharmaceuticals, Inc., a specialty biopharmaceutical company, focuses on developing KRYSTEXXA, a biologic PEGylated uricase in the United States. The KRYSTEXXA is being developed as a treatment for chronic gout in patients refractory to conventional therapy. The company also sells and distributes branded and generic versions of oxandrolone, a drug used to promote weight gain following involuntary weight loss. It sells its products directly to drug wholesalers. The company, formerly known as Bio-Technology General Corp. and changed its name to Savient Pharmaceuticals, Inc. in June 2003. Savient Pharmaceuticals, Inc. was founded in 1980 and is headquartered in East Brunswick, New Jersey.

Advisors’ Opinion:

  • [By James E. Brumley]

    It’s still too soon to say Savient Pharmaceuticals Inc. (NASDAQ:SVNT) is off and running. In fact, the stock’s decidedly NOT off and running yet. But, it’s not too soon to put SVNT on your watchlist of potential breakout candidates, as it’s much closer to a breakout than most anyone can see.

  • [By James E. Brumley]

    Since 2008’s implosion from the stock, the interest in Savient Pharmaceuticals Inc. (NASDAQ:SVNT) has been waning. There was a brief burst of bullishness in September of last year, which stirred the bullish pot a little. But, when SVNT started to fade in October of that year – just as quickly as it had perked up – what lingering hopes there were for the stock finally started to melt away. By the middle of this year, pretty much everyone had written Savient Pharmaceuticals off as a lost cause. Big mistake. Over the last few days, SVNT has almost wiggled its way buck into a bullish zone.

Top 10 High Dividend Stocks For 2015: AVEO Pharmaceuticals Inc.(AVEO)

AVEO Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of cancer therapeutics. The company?s lead product candidate, Tivozanib (AV-951), is a novel, highly potent and selective oral inhibitor of the vascular endothelial growth factor, or VEGF, receptors 1, 2, and 3. It is also leading the clinical development of AV-299, which includes conducting multiple Phase I clinical trials and preparing for the conduct of multiple Phase II clinical trials. The company?s product candidate in preclinical development is AV-203, a potent ErbB3 antibody that has demonstrated efficacy in vivo. It has strategic partnerships with OSI Pharmaceuticals, Inc., Merck, and Biogen Idec, Inc. AVEO Pharmaceuticals was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. The company was founded in 2001 and is based in Cambridge, Massachusetts.

Advisors’ Opinion:

  • [By Laura Brodbeck]

    Thursday

    Earnings Expected From: AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), Kirkland’s, Inc (NASDAQ: KIRK), Dollar General Corporation (NYSE: DG), Stein Mart, Inc. (SMRT: NASDAQ), Mattress Firm Holding Corp. (NASDAQ: MRFM), SeaWorld Entertainment (NYSE: SEAS), Vaalco Energy Inc (NYSE: EGY) Economic Releases Expected: Chinese retail sales, French CPI, Brazilian retail sales, US retail sales, Japanese industrial production

    Friday

  • [By James E. Brumley]

    Looks out Synta Pharmaceuticals Corp. (NASDAQ:SNTA), and AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO), you’re on notice too. Corcept Therapeutics Incorporated (NASDAQ:CORT) is nipping at your heels, and better still, shares of the company looks like they’re about to dole out a sizeable reward to investors who see the writing on the wall.

  • [By Sean Williams]

    Will AVEO be on target?
    The other FDA decision that should have the attention of biotech investors this week is AVEO Pharmaceuticals’ (NASDAQ: AVEO  ) Tivozanib, which is set to go before the FDA’s review panel on Thursday.

Top 10 High Dividend Stocks For 2015: Rite Aid Corp (RAD)

Rite Aid Corporation, incorporated in 1968, is a retail drugstore chain in the United States. As of March 3, 2012, the Company operated drugstores in 31 states across the country and in the District of Columbia. As of March 3, 2012, it operated 4,667 stores. In the Company’s stores, it sells prescription drugs and a range of other merchandise, which it calls front end products. During the fiscal year ended March 3, 2012 (fiscal 2012), prescription drug sales accounted for 68.1% of its total sales. The Company carries a range of front end products, which accounted for 31.9% of its total sales in fiscal 2012. Front end products include over-the-counter medications, health and beauty aids, personal care items, cosmetics, household items, beverages, convenience foods, greeting cards, seasonal merchandise and other everyday and convenience products, as well as photo processing. It offers a variety of products under its private brands, which contributed approximately 17% of it s front end sales in the categories where private brand products were offered in fiscal 2012. As of March 3, 2012, the Company had opened over 2,100 GNC stores-within-Rite Aid-stores. During fiscal 2012, the Company sold two owned operating stores to independent third parties.

During fiscal 2012, its stores filled approximately 295 million prescriptions and served an average of 2.1 million customers per day. The overall average size of each store in its chain is approximately 12,600 square feet. As of March 3, 2012, 60% of its stores were freestanding; 51% of its stores included a drive-thru pharmacy; 24% included one-hour photo shops, and 46% included a GNC store-within-Rite Aid-store. The Company’s customers may also order prescription refills over the Internet through www.riteaid.com, or over the phone through its telephonic automated refill systems for pick up at a Rite Aid store. It has a strategic alliance with GNC, a retailer of vitamin and mineral supp lements.

Advisors’ Opinion:

  • [By Grace L. Williams]

    Shares of CVS have advanced 2.7% to $68.74 at 3:0 p.m., trailing Walgreen’s (WAG) 5.3% rise to $63.87 but besting Rite Aid’s (RAD) 1.5% gain to $5.72.

  • [By Reuters]

    Julio Cortez/AP NEW YORK — Many U.S. retailers had to ramp up promotions last month as shoppers continued to watch their spending during the holiday season, hitting profits at several chains. L Brands (LB) cut its earnings forecast for the holiday quarter Thursday after reporting disappointing December sales at its Victoria Secret and La Senza chains. The company said it had to offer more deals than expected, the second month in a row it has had to do so. Family Dollar Stores (FDO) and teen retailer Zumiez (ZUMZ), which both reported sales declines for December, also slashed their profit forecasts. Even retailers that saw big sales gains, such as Kay Jewelers parent Signet Jewelers (SIG), weren’t spared. “Additional discounting was necessary in a highly promotional retail environment,” Signet Chief Executive Officer Mike Barnes said in a statement. A group of nine U.S. retailers in the Thomson Reuters same-store sales index are expected Thursday to report a sales rise of 1.9 percent in December at stores open at least a year, well below the 7.2 percent increase of a year earlier. Including drugstore chains Walgreen (WAG) and Rite Aid (RAD), analysts estimate the rise at 2.7 percent. Gap (GPS) will report after the markets close Thursday. Faced with reticent shoppers worried about their job prospects and modest economic growth, retailers offered more discounts during the holiday season than a year earlier. Between Nov. 3 and Jan. 4, eight retailers, including Walmart Stores (WMT), Target (T) and Macy’s (M) , increased the number of circulars published by 6 percent and sent 57 percent more promotional emails, according to data prepared for Reuters by MarketTrack. Retailers also had to deal with shoppers who were less willing to go into stores: Data firm ShopperTrak this week said foot traffic had dropped 14.6 percent this holiday season. Walgreen, whose comparable sales of general merchandise rose 2.5 percent in December, said fewer shoppers had com

  • [By Anora Mahmudova]

    Rite Aid Corp. (RAD)  advanced 8.5% after the drugstore chain said same-store sales increased 2.9% in December over the same period a year ago, due to growth in its pharmacy division.

Top 10 High Dividend Stocks For 2015: QC Holdings Inc.(QCCO)

QC Holdings, Inc. provides various retail consumer financial products and services in the United States. The company offers payday loans that provide cash to the customers in exchange for a promissory note with a maturity of two to three weeks. It also provides financial products and services, such as installment loans, credit services, check cashing services, title loans, money transfers, and money orders. In addition, QC Holdings operates as a credit services organization that arranges a third-party lender to make a loan to the consumer and for providing related services to the consumer, including a guarantee of the consumer?s obligation to the third-party lender. Further, the company sells used vehicles and earns finance charges from the related vehicle financing contracts; and provides reconditioning services on its inventory of vehicles, and repair services for its customers. As of As of December 31, 2010, the company operated 523 short-term lending branches in 24 sta tes; and 5 buy here, pay here lots located in Missouri and Kansas. QC Holdings, Inc. was founded in 1984 and is headquartered in Overland Park, Kansas.

Advisors’ Opinion:

  • [By Lisa Levin]

    QC Holdings (NASDAQ: QCCO) shares tumbled 3.68% to reach a new 52-week low of $1.83. QC Holdings shares have dropped 42.60% over the past 52 weeks, while the S&P 500 index has gained 31.67% in the same period.

  • [By Monica Gerson]

    QC Holdings (NASDAQ: QCCO) shares tumbled 2.58% to reach a new 52-week low of $2.27. QC Holdings’ trailing-twelve-month profit margin is 0.60%.

    NewLead Holdings (NASDAQ: NEWL) shares dipped 6.56% to touch a new 52-week low of $0.08 after the company completed the acquisition of titles in the Viking Mine located in Kentucky, USA.